A multicenter study evaluating the efficacy and safety of 12 weeks versus 24 weeks peginterferon alfa-2a 40KD combination therapy with ribavirin in interferon naive patients with chronic hepatitis C genotype 2 or 3 infection
Phase of Trial: Phase IV
Latest Information Update: 01 Apr 2011
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Apr 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 May 2007 The expected completion date for this trial is now 1 Oct 2006.
- 20 Jan 2006 New trial record.